$240.74
-3.10-1.27%
가까이에: Sep 17, 5:00 PM EST
$241.25
-2.59-1.06%
프리마켓: 4:54 AM EST
Benzinga
Benzinga
Benzinga
월요일, 9월 21
Jazz Pharmaceuticals PLC
JAZZNASDAQ
인수합병: Actio Biosciences, Inc was acquired by Jazz Pharmaceuticals (JAZZ) on Tuesday, September 15, 2026 for $820M
Jazz Pharmaceuticals Earnings & Forecasts
Jazz Pharmaceuticals (JAZZ) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Jazz Pharmaceuticals Guidance
Jazz Pharmaceuticals (JAZZ)는 8월 3, 2026에 fiscal year 2026에 대한 가이던스를 마지막으로 발표했습니다. 회사는 해당 기간의 매출을 $4.6B - $4.75B 범위로 예상했습니다.
이전 가이던스와 비교하여 Jazz Pharmaceuticals는 매출 전망치를 이전 범위인 상향 조정됨에서 $4.25B - $4.5B로 상향 조정했습니다.
Jazz Pharmaceuticals은 20과 11월 9, 2022 사이에 8월 3, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 9 times and lowered it 4 times, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $5.94 | $4.49 | $6.16 | $5.43 |
| Actual | $5.71 | $6.34 | $6.64 | $8.13 |
| Surprise | -3.87% | +41.2% | +7.79% | +49.7% |
| Revenue | ||||
| Estimate | $1.11B | $977.6M | $1.17B | $1.11B |
| Actual | $1.21B | $1.61B | $1.20B | $1.13B |
| Surprise | +9.06% | +64.6% | +2.21% | +1.89% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $6.29 | $6.33 | $5.23 | $5.68 |
| Revenue | ||||
| Consensus | $1.21B | $1.23B | — | — |
Earnings & Guidance News
Benzinga
© 2026 Benzinga | All Rights Reserved